iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Zydus Lifesciences Ltd News & Stock Insights Today

936.15
(-0.88%)
Aug 8, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Company

Sectoral

Zydus Wins USFDA’s Tentative Approval to Market Ibrutinib Tablets in US

This development comes after a USFDA inspection at one of Zydus' oncology facilities earlier this year.

24 Jul 2025|03:00 PM
Zydus Lifesciences’ oncology unit gets 2 USFDA observations

In its filing with the bourses, Zydus informed that these observations received were minor, and not related to data integrity.

19 Jun 2025|12:36 PM
Top Stocks for Today - 19th June 2025

Here are some of the stocks that may see significant price movement today: Jio Financial Service, Hero MotoCorp, Abbott India, etc.

19 Jun 2025|06:28 AM
Top Stocks for Today - 12th June 2025

Here are some of the stocks that may see significant price movement today: Hindustan Copper, Maruti Suzuki, Zydus Lifesciences, etc.

12 Jun 2025|06:12 AM
Zydus Lifesciences Gets Clean USFDA Nod for Ankleshwar API Facility

For Zydus, this clean report adds a layer of credibility to its US compliance track record especially since the Ankleshwar facility is a key site for its API exports.

11 Jun 2025|08:40 PM
Zydus Lifesciences Subsidiary Zynext to Acquire 5.9% Stake in Agenus for $16 Million

The acquisition is priced at $7.50 per share and will be completed in cash within 60 days, subject to regulatory approvals

3 Jun 2025|11:05 PM
Zydus Gets USFDA Fast Track Nod for ALS Drug Usnoflast

It provides benefits such as faster approval, priority review and a more open line of communication with the F.D.A.

29 May 2025|10:53 AM
Zydus Lifesciences Gets USFDA Nod for Generic Absorica to Treat Severe Acne

They are the generic form of Absorica, a well-known prescription treatment for severe and hard to treat forms of nodular acne that the patient has not responded well to other treatments with.

24 May 2025|08:15 PM
Zydus Lifesciences Q4 Revenue Rises 18% YoY to ₹6,528 Crore

Consolidated revenue for the March quarter rose 18% YoY to ₹6,528 crore.

22 May 2025|12:16 PM
Zydus Wins USFDA Approval for Cholesterol Drug

The medication is also prescribed to lower the risk of another heart attack in individuals with a past history of myocardial infarction and hyperlipidaemia

30 Apr 2025|11:25 PM
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.